Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
Humans
Anti-Bacterial Agents
/ pharmacology
Pseudomonas aeruginosa
Compassionate Use Trials
Pseudomonas Infections
/ drug therapy
Cephalosporins
/ pharmacology
Ceftazidime
/ pharmacology
Carbapenems
/ pharmacology
Microbial Sensitivity Tests
Drug Resistance, Multiple, Bacterial
/ genetics
Cefiderocol
carbapenem-resistant Pseudomonas aeruginosa
cefiderocol
clinical response
compassionate use
susceptibility breakpoint
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
18 07 2023
18 07 2023
Historique:
medline:
17
7
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa, but its
Identifiants
pubmed: 37347188
doi: 10.1128/aac.00194-23
pmc: PMC10353454
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Ceftazidime
9M416Z9QNR
Carbapenems
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0019423Références
Int J Antimicrob Agents. 2018 Feb;51(2):206-212
pubmed: 29111435
Antimicrob Agents Chemother. 2021 Feb 17;65(3):
pubmed: 33257454
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Microb Drug Resist. 2022 Feb;28(2):161-170
pubmed: 34619049
Pharmacology. 2018;101(5-6):278-284
pubmed: 29471305
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262762
Lancet Infect Dis. 2021 Feb;21(2):213-225
pubmed: 33058798
Lancet Infect Dis. 2018 Dec;18(12):1319-1328
pubmed: 30509675
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541
pubmed: 34291323
Open Forum Infect Dis. 2021 Jun 12;8(7):ofab311
pubmed: 34262990
Microbiol Spectr. 2022 Apr 27;10(2):e0271221
pubmed: 35262394
Expert Rev Anti Infect Ther. 2022 Aug;20(8):1077-1094
pubmed: 35502603
Lancet Infect Dis. 2021 Feb;21(2):226-240
pubmed: 33058795
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Diagn Microbiol Infect Dis. 2021 May;100(1):115302
pubmed: 33516987
Crit Care. 2015 May 06;19:219
pubmed: 25944081
Antimicrob Agents Chemother. 2015 Oct;59(10):6248-55
pubmed: 26248364
Antimicrob Agents Chemother. 2015;59(6):3606-10
pubmed: 25801558
Clin Infect Dis. 2022 Aug 25;75(2):187-212
pubmed: 35439291
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630181
Microbiol Spectr. 2022 Oct 26;10(5):e0169722
pubmed: 36190424
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33820773
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9
pubmed: 27216074
Microb Drug Resist. 2021 Mar;27(3):342-349
pubmed: 32762605
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848004
Drugs. 2021 Dec;81(18):2117-2131
pubmed: 34743315
J Med Microbiol. 2014 Dec;63(Pt 12):1679-1687
pubmed: 25261066
Open Forum Infect Dis. 2022 Sep 09;9(9):ofac456
pubmed: 36168551
Antibiotics (Basel). 2022 Oct 04;11(10):
pubmed: 36290010